Dan

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC). Read More »